Provention Bio has commenced a Phase IIa clinical trial of its investigational humanised bispecific DART molecule, PRV-3279, to treat patients with moderate-to-severe systemic lupus erythematosus (SLE), a chronic autoimmune disease.

The proof-of-concept (POC) PRV-3279 EVAluation In Lupus- Phase 2 (PREVAIL-2) study will examine PRV-3279’s efficacy and safety against placebo. Data from PREVAIL-2 trial is expected in the first half of 2024.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Subject screening has already commenced in the US to identify and recruit nearly 100 patients who will be given six monthly infusions of PRV-3279 or placebo, with primary efficacy readout at 24 weeks.

The double-blind, randomised, placebo-controlled study will investigate PRV-3279 versus placebo, administered every four weeks over a period of five months.

This will be followed by an efficacy and safety follow up for eight weeks.

Assessment of the ability of PRV-3279 to reduce SLE flare is the study’s primary endpoint.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

For this trial, the company will recruit adult subjects with SLE across nearly 28 centres in the US and Hong Kong.

As part of a strategic collaboration, Provention Bio and Hangzhou Zhongmei Huadong Pharmaceutical will develop and market PRV-3279 in Greater China.

In a previous single ascending dose Phase I study and a multiple ascending dose Phase Ib study, PREVAIL-1, PRV-3279 was found to be well-tolerated.

It established proof of mechanism with prolonged inhibition of B cell function.

Provention Bio co-founder and chief scientific officer Francisco Leon said: “PRV-3279 offers an elegant mechanism of action designed to intercept and ameliorate the overactive B cell-driven pathology of lupus and other autoimmune diseases.

“We believe that PRV-3279 allows for rapid inhibition of activated B cells, while sparing non-activated B cells from depletion or inactivation, which may offer the potential for an alternative to current B cell-targeting therapies with a more favorable safety profile.”